These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 12461586)

  • 1. Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy.
    Macías J; Melguizo I; Fernández-Rivera FJ; García-García A; Mira JA; Ramos AJ; Rivera JM; Pineda JA
    Eur J Clin Microbiol Infect Dis; 2002 Nov; 21(11):775-81. PubMed ID: 12461586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
    Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
    Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating hepatitis C in HIV-HCV coinfected patients.
    Tossing G
    Infection; 2002 Oct; 30(5):329-31. PubMed ID: 12420736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of GB virus C viremia on patients with HIV type 1 infection in the era of highly active antiretroviral therapy.
    Sheng WH; Hung CC; Wu RJ; Wang JT; Chen PJ; Chang SC; Kao JH
    Clin Infect Dis; 2007 Feb; 44(4):584-90. PubMed ID: 17243064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study.
    Murillas J; Rimola A; Laguno M; de Lazzari E; Rascón J; Agüero F; Blanco JL; Moitinho E; Moreno A; Miró JM;
    Liver Transpl; 2009 Sep; 15(9):1133-41. PubMed ID: 19718643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study.
    Sheng WH; Hung CC; Kao JH; Chang SY; Chen MY; Hsieh SM; Chen PJ; Chang SC
    Clin Infect Dis; 2007 Apr; 44(7):988-95. PubMed ID: 17342655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area.
    Martínez E; Milinkovic A; Buira E; de Lazzari E; León A; Larrousse M; Loncá M; Laguno M; Blanco JL; Mallolas J; García F; Miró JM; Gatell JM
    HIV Med; 2007 May; 8(4):251-8. PubMed ID: 17461853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.
    Omland LH; Weis N; Skinhøj P; Laursen A; Christensen PB; Nielsen HI; Møller A; Engsig F; Sørensen HT; Obel N
    HIV Med; 2008 May; 9(5):300-6. PubMed ID: 18400077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy.
    Tedaldi EM; Baker RK; Moorman AC; Alzola CF; Furhrer J; McCabe RE; Wood KC; Holmberg SD;
    Clin Infect Dis; 2003 Feb; 36(3):363-7. PubMed ID: 12539079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection.
    Norris S; Taylor C; Muiesan P; Portmann BC; Knisely AS; Bowles M; Rela M; Heaton N; O'Grady JG
    Liver Transpl; 2004 Oct; 10(10):1271-8. PubMed ID: 15376307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival in HIV-infected patients is associated with hepatitis C virus infection and injecting drug use since the use of highly active antiretroviral therapy in the Lyon observational database.
    Voirin N; Trépo C; Miailhes P; Touraine JL; Chidiac C; Peyramond D; Livrozet JM; Ritter J; Chevallier P; Fabry J; Allard R; Vanhems P
    J Viral Hepat; 2004 Nov; 11(6):559-62. PubMed ID: 15500557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study.
    Anderson KB; Guest JL; Rimland D
    Clin Infect Dis; 2004 Nov; 39(10):1507-13. PubMed ID: 15546088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of the incidence and aetiology of fever of unknown origin (FUO), and survival in HIV-infected patients after HAART (Highly Active Antiretroviral Therapy).
    Abellán-Martínez J; Guerra-Vales JM; Fernández-Cotarelo MJ; González-Alegre MT
    Eur J Intern Med; 2009 Sep; 20(5):474-7. PubMed ID: 19712847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.
    Ramírez-Amador V; Ponce-de-León S; Anaya-Saavedra G; Crabtree Ramírez B; Sierra-Madero J
    Clin Infect Dis; 2007 Oct; 45(7):925-32. PubMed ID: 17806063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.
    Rockstroh JK; Mocroft A; Soriano V; Tural C; Losso MH; Horban A; Kirk O; Phillips A; Ledergerber B; Lundgren J;
    J Infect Dis; 2005 Sep; 192(6):992-1002. PubMed ID: 16107951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.
    Macías J; Mira JA; López-Cortés LF; Santos I; Girón-González JA; González-Serrano M; Merino D; Hernández-Quero J; Rivero A; Merchante N; Trastoy M; Carrillo-Gómez R; Arizcorreta-Yarza A; Gómez-Mateos J; Pineda JA
    Antivir Ther; 2006; 11(7):839-46. PubMed ID: 17302246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
    Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
    AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C.
    García-Samaniego J; Rodríguez M; Berenguer J; Rodríguez-Rosado R; Carbó J; Asensi V; Soriano V
    Am J Gastroenterol; 2001 Jan; 96(1):179-83. PubMed ID: 11197250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver transplantation in HIV/hepatitis co-infection.
    Miro JM; Aguero F; Laguno M; Tuset M; Cervera C; Moreno A; Garcia-Valdecasas JC; Rimola A;
    J HIV Ther; 2007 Mar; 12(1):24-35. PubMed ID: 17589393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.